Pharmacy benefit managers and health carriers required to include lower-cost drugs in their formularies, and formulary structure and formulary tiering for each health plan required to give preference to the drug with the lowest out-of-pocket cost to the patient.
Impact
Should HF1076 be enacted, it will significantly alter the landscape of drug formularies within health plans across the state. The bill requires that formularies not only include the lowest-cost drugs but also prohibits imposing barriers such as prior authorization or step therapy for these preferred medications. This change is expected to enhance patient access to affordable medications, which could lead to overall better health outcomes and potentially reduce healthcare expenditures for individuals who rely on prescription drugs.
Summary
HF1076 is a legislative proposal in Minnesota aimed at enhancing healthcare affordability by mandating that pharmacy benefit managers (PBMs) and health carriers include lower-cost medications within their formularies. This bill specifically targets the pricing structures of drugs by requiring such entities to give preference to medications with the lowest out-of-pocket costs for patients. It applies to various categories of drugs, including brand-name drugs, generic drugs, and biologics, ensuring that if a higher-cost drug is included in a formulary, its lower-cost alternatives must also be listed and accessible.
Contention
Despite its potential benefits, the bill may face opposition from various stakeholders within the pharmaceutical industry and healthcare providers. Concerns may arise over the operational impacts on PBMs and health carriers, who may argue that mandated changes to formulary structures could undermine their ability to negotiate prices and manage healthcare costs effectively. Additionally, there may be debates regarding the implications of prioritizing drug costs over other factors such as quality and clinical outcomes, which could lead to a contentious discussion among legislators and healthcare advocates.
Similar To
Pharmacy benefit managers and health carriers inclusion of lower-cost drugs in formularies requirement provision and lowest out-of-pocket-cost drug to patient formulary tiering preference provision
Pharmacy benefit managers and health carriers required to include lower-cost drugs in their formularies, and formulary structure and formulary tiering for each health plan required to give preference to drug with lowest out-of-pocket cost to patient.
Manufacturers required to report and maintain prescription drug prices, filing of health plan prescription drug formularies required, health care coverage provisions modified, prescription benefit tool requirements established, and prescription drug benefit transparency and disclosure required.
Pharmacy benefit managers and health carriers required to use prescription drug rebates and other compensation to benefit covered persons, and report required.
Generic or off-patent drugs; excessive price increases prohibited, attorney general authorized to take action against price increases, sale withdrawal prohibited, prescription drug affordability board and advisory council established, prescription drug cost reviews and remedies provided, and money appropriated.
Pharmacy benefit manager business practices modified, pharmacy benefit manager general reimbursement practices established, and maximum allowable cost pricing requirements modified.
Pharmacy benefit managers and health carriers inclusion of lower-cost drugs in formularies requirement provision and lowest out-of-pocket-cost drug to patient formulary tiering preference provision
Pharmacy benefit managers and health carriers required to include lower-cost drugs in their formularies, and formulary structure and formulary tiering for each health plan required to give preference to drug with lowest out-of-pocket cost to patient.
Resolve, Directing the Superintendent of Insurance to Collect Data from Health Insurers Related to Prescription Drug Coverage of Generic Drugs and Biosimilars
To Mandate The Use Of Biosimilar Medicines Under Health Benefit Plans; To Require A Healthcare Provider To Prescribe Biosimilar Medicines; And To Improve Access To Biosimilar Medicines.